Skip to content

Study · Systematic review · 2026

10 results

Use of incretin receptor agonists in patients submitted to metabolic bariatric surgery - a systematic review and meta-analysis.

Santos-Pereira M, Frutuoso JF, Pereira SS, Guimarães M, Monteiro MP

Frontiers in endocrinology26 Aug 2026

PMID42718598 (opens in a new tab)PMCIDPMC13553220 (opens in a new tab)DOI10.3389/fendo.2026.1870008 (opens in a new tab)PepBankPUB-42718598
Download PDFPubMedAsk about this study
Jump to 10 results

Summary

IntroductionMetabolic bariatric surgery is a highly effective weight-loss intervention. Nevertheless, a non-negligible proportion of patients experience a suboptimal clinical response, which may present as insufficient weight loss or weight regain after an initial loss. In these cases, weight management pharmacotherapy can be considered. We aimed to conduct a systematic review and meta-analysis of the best available data on the use of incretin receptor agonists, liraglutide, semaglutide, and tirzepatide, in patients previously submitted to metabolic bariatric surgery.MethodsWe searched PubMed, Scopus, and Web of Science, for original studies that evaluated weight loss and adverse events in adults submitted to metabolic bariatric surgery one year or more before receiving treatment with these drugs.ResultsTwenty-seven papers (n=27) were included in this systematic review, of which nineteen (n=19) were used in the meta-analysis. After treatment with incretin receptor agonists, patients who underwent metabolic bariatric surgery, experienced significant weight loss. Meta-analysis showed, at 12 months, a total weight loss of 9.22% with liraglutide and of 9.02% with semaglutide. At 6 months, a mean difference in total weight loss of 4.23% was presented in favor of tirzepatide as compared to semaglutide. No serious adverse events were observed and most reported side effects were non-serious, consisting primarily of mild gastrointestinal symptoms.DiscussionThis data suggests that incretin receptor agonist treatment after metabolic bariatric surgery demonstrated the ability to achieve significant weight loss with a good safety profile, particularly in patients with a suboptimal clinical response, and thus may serve as an alternative rescue therapy to revisional surgery. However, given the substantial heterogeneity across studies, these findings should be interpreted with caution.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022371697, identifier CRD42022371697.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study10

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In adults previously undergoing bariatric surgery, liraglutide was associated with 9.22% total weight loss at 12 months; the exact reference was unstated.

    In plain wordsIn adults after bariatric surgery, liraglutide was linked to 9.22% total weight loss at 12 months; its reference was unstated.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody-weight reduction at 12 months
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Total weight loss
    9.22%
    12-month assessment;exact reference unspecified

    Source sentences

    Summary
    Meta-analysis showed, at 12 months, a total weight loss of 9.22% with liraglutide and of 9.02% with semaglutide.
    3 context sentences
    Summary · context
    We aimed to conduct a systematic review and meta-analysis of the best available data on the use of incretin receptor agonists, liraglutide, semaglutide, and tirzepatide, in patients previously submitted to metabolic bariatric surgery.
    Summary · context
    We searched PubMed, Scopus, and Web of Science, for original studies that evaluated weight loss and adverse events in adults submitted to metabolic bariatric surgery one year or more before receiving treatment with these drugs.
    Summary · context
    Twenty-seven papers (n=27) were included in this systematic review, of which nineteen (n=19) were used in the meta-analysis.
  2. 02HumanSystematic reviewEfficacy outcome

    In adults previously undergoing bariatric surgery, semaglutide was associated with 9.02% total weight loss at 12 months; the exact reference was unstated.

    In plain wordsIn adults after bariatric surgery, semaglutide was linked to 9.02% total weight loss at 12 months; its reference was unstated.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody-weight reduction at 12 months
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Total weight loss
    9.02%
    12-month assessment;exact reference unspecified

    Source sentences

    Summary
    Meta-analysis showed, at 12 months, a total weight loss of 9.22% with liraglutide and of 9.02% with semaglutide.
    3 context sentences
    Summary · context
    We aimed to conduct a systematic review and meta-analysis of the best available data on the use of incretin receptor agonists, liraglutide, semaglutide, and tirzepatide, in patients previously submitted to metabolic bariatric surgery.
    Summary · context
    We searched PubMed, Scopus, and Web of Science, for original studies that evaluated weight loss and adverse events in adults submitted to metabolic bariatric surgery one year or more before receiving treatment with these drugs.
    Summary · context
    Twenty-seven papers (n=27) were included in this systematic review, of which nineteen (n=19) were used in the meta-analysis.
  3. 03HumanSystematic reviewEfficacy outcome

    In adults after bariatric surgery, tirzepatide had greater weight-reduction magnitude than semaglutide at 6 months (reported MD 4.23% in favor of tirzepatide).

    In plain wordsIn adults after bariatric surgery, tirzepatide had greater weight-reduction magnitude than semaglutide at 6 months.

    Peptide
    Tirzepatide
    Outcome
    IncreaseMagnitude of total weight reduction at 6 months
    Study

    n: not reported in source

    Comparator
    Semaglutide
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Mean difference in total weight loss
    4.23%
    6 months;reported contrast favors tirzepatide over semaglutide

    Source sentences

    Summary
    At 6 months, a mean difference in total weight loss of 4.23% was presented in favor of tirzepatide as compared to semaglutide.
    3 context sentences
    Summary · context
    We aimed to conduct a systematic review and meta-analysis of the best available data on the use of incretin receptor agonists, liraglutide, semaglutide, and tirzepatide, in patients previously submitted to metabolic bariatric surgery.
    Summary · context
    We searched PubMed, Scopus, and Web of Science, for original studies that evaluated weight loss and adverse events in adults submitted to metabolic bariatric surgery one year or more before receiving treatment with these drugs.
    Summary · context
    Twenty-seven papers (n=27) were included in this systematic review, of which nineteen (n=19) were used in the meta-analysis.
  4. 04HumanSystematic reviewEfficacy outcome

    In adults after bariatric surgery, semaglutide had smaller weight-reduction magnitude than tirzepatide at 6 months (reported MD 4.23% in favor of tirzepatide).

    In plain wordsIn adults after bariatric surgery, semaglutide had smaller weight-reduction magnitude than tirzepatide at 6 months.

    Peptide
    Semaglutide
    Outcome
    DecreaseMagnitude of total weight reduction at 6 months
    Study

    n: not reported in source

    Comparator
    Tirzepatide
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Mean difference in total weight loss
    4.23%
    6 months;reported contrast favors tirzepatide over semaglutide

    Source sentences

    Summary
    At 6 months, a mean difference in total weight loss of 4.23% was presented in favor of tirzepatide as compared to semaglutide.
    3 context sentences
    Summary · context
    We aimed to conduct a systematic review and meta-analysis of the best available data on the use of incretin receptor agonists, liraglutide, semaglutide, and tirzepatide, in patients previously submitted to metabolic bariatric surgery.
    Summary · context
    We searched PubMed, Scopus, and Web of Science, for original studies that evaluated weight loss and adverse events in adults submitted to metabolic bariatric surgery one year or more before receiving treatment with these drugs.
    Summary · context
    Twenty-seven papers (n=27) were included in this systematic review, of which nineteen (n=19) were used in the meta-analysis.

Studies that did not test the peptide alone6

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 05HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome

    In reviewed adults after bariatric surgery, across incretin drugs including liraglutide, no serious adverse events were observed.

    In plain wordsIn reviewed adults after bariatric surgery, across incretin drugs including liraglutide, no serious side effects were observed.

    Peptide
    Liraglutide
    Outcome
    Not applicableSerious adverse events
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body

    Source sentences

    Summary
    No serious adverse events were observed and most reported side effects were non-serious, consisting primarily of mild gastrointestinal symptoms.
    3 context sentences
    Summary · context
    We aimed to conduct a systematic review and meta-analysis of the best available data on the use of incretin receptor agonists, liraglutide, semaglutide, and tirzepatide, in patients previously submitted to metabolic bariatric surgery.
    Summary · context
    We searched PubMed, Scopus, and Web of Science, for original studies that evaluated weight loss and adverse events in adults submitted to metabolic bariatric surgery one year or more before receiving treatment with these drugs.
    Summary · context
    Twenty-seven papers (n=27) were included in this systematic review, of which nineteen (n=19) were used in the meta-analysis.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 06HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome

    In reviewed adults after bariatric surgery, across incretin drugs including semaglutide, no serious adverse events were observed.

    In plain wordsIn reviewed adults after bariatric surgery, across incretin drugs including semaglutide, no serious side effects were observed.

    Peptide
    Semaglutide
    Outcome
    Not applicableSerious adverse events
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body

    Source sentences

    Summary
    No serious adverse events were observed and most reported side effects were non-serious, consisting primarily of mild gastrointestinal symptoms.
    3 context sentences
    Summary · context
    We aimed to conduct a systematic review and meta-analysis of the best available data on the use of incretin receptor agonists, liraglutide, semaglutide, and tirzepatide, in patients previously submitted to metabolic bariatric surgery.
    Summary · context
    We searched PubMed, Scopus, and Web of Science, for original studies that evaluated weight loss and adverse events in adults submitted to metabolic bariatric surgery one year or more before receiving treatment with these drugs.
    Summary · context
    Twenty-seven papers (n=27) were included in this systematic review, of which nineteen (n=19) were used in the meta-analysis.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  3. 07HumanNot a test of Tirzepatide aloneSystematic reviewSafety outcome

    In reviewed adults after bariatric surgery, across incretin drugs including tirzepatide, no serious adverse events were observed.

    In plain wordsIn reviewed adults after bariatric surgery, across incretin drugs including tirzepatide, no serious side effects were observed.

    Peptide
    Tirzepatide
    Outcome
    Not applicableSerious adverse events
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body

    Source sentences

    Summary
    No serious adverse events were observed and most reported side effects were non-serious, consisting primarily of mild gastrointestinal symptoms.
    3 context sentences
    Summary · context
    We aimed to conduct a systematic review and meta-analysis of the best available data on the use of incretin receptor agonists, liraglutide, semaglutide, and tirzepatide, in patients previously submitted to metabolic bariatric surgery.
    Summary · context
    We searched PubMed, Scopus, and Web of Science, for original studies that evaluated weight loss and adverse events in adults submitted to metabolic bariatric surgery one year or more before receiving treatment with these drugs.
    Summary · context
    Twenty-seven papers (n=27) were included in this systematic review, of which nineteen (n=19) were used in the meta-analysis.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  4. 08HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome

    In reviewed adults after bariatric surgery, across incretin drugs including liraglutide, most reported side effects were non-serious, primarily mild gastrointestinal symptoms.

    In plain wordsIn reviewed adults after bariatric surgery, across incretin drugs including liraglutide, reported side effects were mainly mild stomach/bowel symptoms.

    Peptide
    Liraglutide
    Outcome
    Not applicableMild gastrointestinal symptoms
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal

    Source sentences

    Summary
    No serious adverse events were observed and most reported side effects were non-serious, consisting primarily of mild gastrointestinal symptoms.
    3 context sentences
    Summary · context
    We aimed to conduct a systematic review and meta-analysis of the best available data on the use of incretin receptor agonists, liraglutide, semaglutide, and tirzepatide, in patients previously submitted to metabolic bariatric surgery.
    Summary · context
    We searched PubMed, Scopus, and Web of Science, for original studies that evaluated weight loss and adverse events in adults submitted to metabolic bariatric surgery one year or more before receiving treatment with these drugs.
    Summary · context
    Twenty-seven papers (n=27) were included in this systematic review, of which nineteen (n=19) were used in the meta-analysis.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  5. 09HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome

    In reviewed adults after bariatric surgery, across incretin drugs including semaglutide, most reported side effects were non-serious, primarily mild gastrointestinal symptoms.

    In plain wordsIn reviewed adults after bariatric surgery, across incretin drugs including semaglutide, reported side effects were mainly mild stomach/bowel symptoms.

    Peptide
    Semaglutide
    Outcome
    Not applicableMild gastrointestinal symptoms
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal

    Source sentences

    Summary
    No serious adverse events were observed and most reported side effects were non-serious, consisting primarily of mild gastrointestinal symptoms.
    3 context sentences
    Summary · context
    We aimed to conduct a systematic review and meta-analysis of the best available data on the use of incretin receptor agonists, liraglutide, semaglutide, and tirzepatide, in patients previously submitted to metabolic bariatric surgery.
    Summary · context
    We searched PubMed, Scopus, and Web of Science, for original studies that evaluated weight loss and adverse events in adults submitted to metabolic bariatric surgery one year or more before receiving treatment with these drugs.
    Summary · context
    Twenty-seven papers (n=27) were included in this systematic review, of which nineteen (n=19) were used in the meta-analysis.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  6. 10HumanNot a test of Tirzepatide aloneSystematic reviewSafety outcome

    In reviewed adults after bariatric surgery, across incretin drugs including tirzepatide, most reported side effects were non-serious, primarily mild gastrointestinal symptoms.

    In plain wordsIn reviewed adults after bariatric surgery, across incretin drugs including tirzepatide, reported side effects were mainly mild stomach/bowel symptoms.

    Peptide
    Tirzepatide
    Outcome
    Not applicableMild gastrointestinal symptoms
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal

    Source sentences

    Summary
    No serious adverse events were observed and most reported side effects were non-serious, consisting primarily of mild gastrointestinal symptoms.
    3 context sentences
    Summary · context
    We aimed to conduct a systematic review and meta-analysis of the best available data on the use of incretin receptor agonists, liraglutide, semaglutide, and tirzepatide, in patients previously submitted to metabolic bariatric surgery.
    Summary · context
    We searched PubMed, Scopus, and Web of Science, for original studies that evaluated weight loss and adverse events in adults submitted to metabolic bariatric surgery one year or more before receiving treatment with these drugs.
    Summary · context
    Twenty-seven papers (n=27) were included in this systematic review, of which nineteen (n=19) were used in the meta-analysis.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 4Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Versions 2 to 3

    9 Oct 2026, 03:07 UTC

    The same notice was added 2 times, first on 9 Oct 2026, 03:06 UTC. The status did not change between them.

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.